Abdelfattah M Attallah1, Mohamed M Omran2, Ahmed A Attallah3, Mohamed A Abdelrazek3, Khaled Farid4, Ibrahim El-Dosoky5. 1. R&D Department, Biotechnology Research Center, PO Box (14), 23 July Street, Industrial Zone, New Damietta, 34517, Egypt. amattallah@hotmail.com. 2. Faculty of Science, Helwan University, Cairo, Egypt. 3. R&D Department, Biotechnology Research Center, PO Box (14), 23 July Street, Industrial Zone, New Damietta, 34517, Egypt. 4. Tropical Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 5. Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Abstract
BACKGROUND: Small-sized HCC can be effectively cured by surgery with good clinical outcomes. A highly sensitive HCC α-fetoprotein routine test (HCC-ART) for HCC diagnosis as well as a simplied form of the HCC-ART were reported in the British Journal of Cancer. Here, we verified and studied the applicability of the HCC-ART to the detection of early-stage HCC. METHODS: 341 cirrhotic patients and 318 HCC patients were included in this study. For each, the HCC-ART score was calculated, and then the sensitivity, specificity, and results of an ROC curve analysis were compared between the HCC-ART and AFP when these biomarkers were used to detect small-sized HCC. RESULTS: Different HCC-ART cutoffs were set for the detection of different tumor sizes. The HCC-ART (AUC = 0.871, 70% sensitivity, 97% specificity) and the simplified HCC-ART (AUC = 0.934, 82% sensitivity, 100% specificity) were found to have high predictive power when attempting to separate cirrhotic patients from those with small-sized HCC. The simplified HCC-ART score was superior to AFP for determining stages according to the early Okuda (0.950 AUC, 84% sensitivity, 99% specificity), CLIP (0.945 AUC, 84% sensitivity, 99% specificity), and BCLC (1.000 AUC, 100% sensitivity, 99% specificity) staging systems. The simplified HCC-ART score was more strongly correlated than AFP and other staging systems with HCC tumor size (P < 0.0001; r = 0.8). CONCLUSION: The HCC-ART is superior to AFP for diagnosing early-stage HCC. Due to its advantages of minimal variability and a wide continuous scale for assessing HCC severity, the simplified HCC-ART has the potential to be more widely used than the original HCC-ART.
BACKGROUND: Small-sized HCC can be effectively cured by surgery with good clinical outcomes. A highly sensitive HCC α-fetoprotein routine test (HCC-ART) for HCC diagnosis as well as a simplied form of the HCC-ART were reported in the British Journal of Cancer. Here, we verified and studied the applicability of the HCC-ART to the detection of early-stage HCC. METHODS: 341 cirrhotic patients and 318 HCC patients were included in this study. For each, the HCC-ART score was calculated, and then the sensitivity, specificity, and results of an ROC curve analysis were compared between the HCC-ART and AFP when these biomarkers were used to detect small-sized HCC. RESULTS: Different HCC-ART cutoffs were set for the detection of different tumor sizes. The HCC-ART (AUC = 0.871, 70% sensitivity, 97% specificity) and the simplified HCC-ART (AUC = 0.934, 82% sensitivity, 100% specificity) were found to have high predictive power when attempting to separate cirrhotic patients from those with small-sized HCC. The simplified HCC-ART score was superior to AFP for determining stages according to the early Okuda (0.950 AUC, 84% sensitivity, 99% specificity), CLIP (0.945 AUC, 84% sensitivity, 99% specificity), and BCLC (1.000 AUC, 100% sensitivity, 99% specificity) staging systems. The simplified HCC-ART score was more strongly correlated than AFP and other staging systems with HCC tumor size (P < 0.0001; r = 0.8). CONCLUSION: The HCC-ART is superior to AFP for diagnosing early-stage HCC. Due to its advantages of minimal variability and a wide continuous scale for assessing HCC severity, the simplified HCC-ART has the potential to be more widely used than the original HCC-ART.
Entities:
Keywords:
Blood biomarkers; Diagnosis; Early stage; HCC-ART score; Hepatocellular carcinoma
Authors: Kelly A Gebo; Geetanjali Chander; Mollie W Jenckes; Khalil G Ghanem; H Franklin Herlong; Michael S Torbenson; Samer S El-Kamary; Eric B Bass Journal: Hepatology Date: 2002-11 Impact factor: 17.425
Authors: E Giannini; D Risso; F Botta; P Romagnoli; F Malfatti; A Fumagalli; E Testa; E Podestà; B Chiarbonello; S Polegato; R Testa Journal: J Intern Med Date: 2004-03 Impact factor: 8.989
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396